• Clinical trial data demonstrates how Bio-Techne’s spatial biology technology and Nucleai’s AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients.

• Bio-Techne’s COMET™ platform and Nucleai’s multimodal spatial operating system profiled 42 biopsies, revealing immune cell interactions linked to clinical outcomes.

• Study selected by the scientific committee as one of the top 150 abstracts from over 1,200 submissions at SITC 2025

Minneapolis, Minnesota and Tel Aviv, Israel — November 4, 2025 — Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, and Nucleai, a leader in AI-powered multimodal spatial biology for precision medicine, today announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.

The study, conducted in collaboration with Professor Paolo Ascierto, Full Professor of Oncology at the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, showcases the significance of spatial biology in translational research by combining, for the first time, an immuno-oncology (IO) multiplex immunofluorescence (mIF) panel with advanced AI-driven multimodal biomarker analysis.

Study Overview

Using the COMET platform and a 28-plex mIF panel, researchers profiled 42 pre-treatment biopsies from patients with metastatic melanoma. Nucleai’s multimodal spatial operating system integrated high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB).

Key Findings

• Arm A (MAPKi → ICB): Immune activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells are linked to better outcomes.

• Arm B (ICB → MAPKi): PD-1+ CD8 T-cells in the tumor invasive margin and their interactions with PD-L1+ CD4 T-cells correlated with improved survival.

• Arm C (MAPKi → ICB → MAPKi): APC-T-cell interactions in tumor margins associated with better outcomes; macrophage interactions in outer tumor microenvironment (TME) indicated poorer prognosis.

The study shows that where immune cells are located and how they interact within the tumor matters significantly for treatment success. By using AI and spatial biology to map these immune niches, researchers can better predict which patients will benefit from specific therapies moving toward more personalized and effective cancer treatment.

“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology,” said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne

“Our multimodal spatial operating system enables integration of high-plex imaging, data, and clinical information to identify predictive biomarkers in clinical settings,” said Avi Veidman, CEO of Nucleai. “This collaboration shows how precision medicine products can become more accurate, explainable, and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone.”

“The SECOMBIT trial is a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study,” added Dr. Ascierto.

Availability at SITC 2025

Bio-Techne’s full spatial biology portfolio—including the new ProximityScope™ assay and the extended SPYRE™ portfolio will be showcased at Booth #603 at SITC 2025. Visual data from the SECOMBIT study will also be presented in Poster # 528, alongside additional immuno-oncology research from Bio-Techne and its collaborators.

# # #

About Bio-Techne 

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.

About Nucleai

Nucleai is an AI-powered multimodal spatial biology company, transforming tissue imaging into actionable insights for drug development and diagnostics. Nucleai’s multimodal spatial operating system integrates high-plex spatial proteomics, histopathology, and clinical data to identify predictive spatial biomarkers and power the development of next-generation precision medicine products. Nucleai partners with leading pharmaceutical, diagnostic, and academic institutions globally. Learn more at https://nucleai.ai/.

Media Contacts:  

Bio-Techne

Corporate Communications – [email protected]

Investor Relations — [email protected]

Nucleai

Press – [email protected]

 

MINNEAPOLIS, MN – November 05, 2024 – Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne’s Lunaphore branded end-to-end spatial biology offering, including its complete range of instruments (COMET) and kits that offer high-value solutions for the translational research community.

COMET, a best-in-class spatial biology platform, seamlessly integrates into standard clinical research workflows. Using off-the-shelf, clinically IHC-validated antibodies, new panels can be quickly developed and validated. Additionally, COMET enables high-plex workflow automation, adding unique value to clinical studies by facilitating robust and timely decision-making in treatment strategies.

Research conducted in collaboration with Prof. Paolo Ascierto, National Tumor Institute Fondazione G. Pascale, and leading AI-powered spatial biomarker and diagnostics company, Nucleai, uncovered potential tumor microenvironment (TME) features predictive of response to therapy. In the cohort study of immunotherapy-treated metastatic melanoma patients, a comprehensive spatial immuno-oncology multiplex immunofluorescence (mIF) panel was combined for the first time with advanced AI-powered biomarker analysis. The findings highlight that the fully- automated workflow and AI tissue analytics can be applied more broadly in immunotherapy drug development to enhance the understanding of treatment efficacy, ultimately improving patient outcomes.

“COMET enables the identification of multiple biomarkers and spatial interactions between different cell types within the TME,“ said Prof. Ascierto. “Its use together with Nucleai’s AI spatial biomarker platform in predicting therapy response for patients enrolled in the SECOMBIT[1]  study, marks the first application of this innovative technology in a clinical trial, representing a significant step toward identifying predictive biomarkers.”

“This study demonstrates our shared vision to accelerate predictive spatial biomarker development and showcases the COMET platform’s unique potential in enabling the design of more effective immunotherapy strategies in advanced cancers such as metastatic melanoma,“ said Dr. Matt McManus, President of Bio-Techne’s Diagnostics & Spatial Biology Segment. “We’re committed to pushing the boundaries of healthcare by advancing spatial biology in clinical research and ultimately improve patient outcomes.”

Another study conducted in collaboration with Prof. Janis Taube, Johns Hopkins University School of Medicine, demonstrates the potential of the novel amplification technique on the COMET platform, allowing scientists to comprehensively profile the TME, leading the way for improved insights in clinical research.

At this year’s Society for Immunotherapy of Cancer’s (SITC) Annual Meeting novel data sets will be presented, showcasing the scientific advancements brought by COMET.

To learn more about Lunaphore’s poster presentations and activities at SITC, please visit: https://lunaphore.com/news/events

 

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

About Lunaphore

Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.

About COMET™

COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET™ enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/

 

 

Bio-Techne Corporation (NASDAQ: TECH)

David Clair, Vice President, Investor Relations & Corporate Development

[email protected]

612-656-4416

 

For further information on Lunaphore:

Irene Tamayo, Senior Director, Product Strategy and Marketing

[email protected]

[1]

An international study focusing on the different sequences of treatment in BRAF-mutated advanced melanoma patients.

MINNEAPOLIS – September 26, 2024 – Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET™, a best-in-class spatial biology platform, to Discovery’s global suite of biospecimen products and specialty lab services supporting customers with clinical research.

The strategic partnership leverages Lunaphore’s COMET technology, the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities, with Discovery’s scientific expertise to advance immuno-oncology, immunology, neuroscience, and infectious disease research across all development stages at a new level of precision and speed. Discovery’s Lunaphore COMET Hyperplex Immunofluorescence Services will facilitate the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification, and translational medicine.

“We are excited to expand our specialty lab services offering to include Lunaphore COMET Hyperplex Immunofluorescence Services,” said Discovery CEO Greg Herrema. “By integrating COMET with Discovery’s molecular pathology expertise, this partnership is poised to drive biomedical research breakthroughs.  This new service combined with our rigorous regulatory compliance processes will provide pharmaceutical companies with the ability to develop Clinical Laboratory Improvement Amendment (CLIA) compliant hyperplex tests.”

“Discovery Life Sciences stands out as a pioneering global leader offering COMET’s cutting-edge capabilities to biopharmaceutical clients across the U.S., Europe, and  APAC,” said Matt McManus, President of Bio-Techne’s Diagnostics & Genomics Segment. “This strategic partnership furthers Bio-Techne’s commitment to push the boundaries of research to transform patient care. I look forward to seeing COMET accelerate the adoption of spatial biology techniques in clinical trials.”

 

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Contact: David Clair, Vice President, Investor Relations & Corporate Development
[email protected]
612-656-4416

 

About Lunaphore

Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker signatures with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.

About COMET™

Lunaphore COMET™ is the only fully-automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET platform, please visit: https://lunaphore.com/products/comet/

About Discovery Life Sciences

Discovery Life Sciences is a leading global provider of biospecimen products and specialty lab services. The company enables the discovery and development of therapies and diagnostics by providing pharmaceutical, biotech, and diagnostic companies with the highest quality biospecimens, in vitro preclinical solutions, and cell and gene therapy starting materials. Additionally, Discovery offers a complete suite of specialty lab services, including genomics, proteomics, molecular pathology, and cell biology, to support both prospective and retrospective clinical trials. For more information, visit dls.com.

For further information on Lunaphore:

Lindsey Rodger, Head of Communications
[email protected]

MINNEAPOLIS, MN – March 28, 2024 – Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore, part of Bio-Techne’s Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.

Lunaphore’s flagship COMET technology is the only fully-automated,  high-throughput, hyperplex platform with superior tissue profiling capabilities, which performs protein detection with standard, non-conjugated antibodies. The Nikon BioImaging Lab is a research and innovation hub recently established by Nikon in the Greater Boston area, Massachusetts with the overarching mission of providing contract imaging solutions, AI-enhanced analysis and bioassay development services to foster research and drug discovery.  Together, Lunaphore and the Nikon BioImaging Lab will be able to leverage their complementary expertise in microscopy-based imaging and analysis to bring COMET technology and spatial biology to the greater scientific community.

Through this partnership, in addition to access to the COMET platform, Nikon customers will also benefit from HORIZON™, Lunaphore’s image analysis software designed for analyzing COMET hyperplex images, to further streamline image analysis workflow. Researchers and clinicians can leverage the universal end-to-end product suite to unlock the full potential of spatial biology for their research objectives.

“The deployment of COMET at the Nikon BioImaging Lab ensures that an expanded base of customers and researchers across the US can access the cutting-edge capabilities of our spatial biology solutions,” said Matt McManus, President of Bio-Techne’s Diagnostics & Genomics Segment. “This strategic partnership reflects Bio-Techne and Nikon’s shared commitment to bringing outstanding innovation to scientists and helping push the boundaries of research.”

“Nikon is very excited to have a strategic partnership with Lunaphore,” said Toshisada Matsuba, President, CEO at Nikon Instruments Inc.

“We are pleased to provide spatial biology assay services using Lunaphore’s automated platform for hyperplex immunofluorescence alongside the broad range of imaging solutions we offer with our Nikon microscopes,” added Fumiki  Yanagawa, General Manager at the Nikon BioImaging Lab. “Spatial biology is a dynamic area of innovation that will shed new light on healthcare and further our understanding of human disease and health.”

 

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

About Lunaphore

Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.

About COMET™

COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET™ enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/

About Nikon Instruments Inc.

Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. For more information, please visit https://www.microscope.healthcare.nikon.com or contact us at 1-800-52-NIKON.

 

About Nikon BioImaging Lab

The Nikon BioImaging Lab, established in Boston, is a fully equipped laboratory housing a wide range of advanced microscopes and other critical instrumentation, and staffed by experienced scientists who collaborate with pharma, biotech and academic customers to develop solutions for their wide-ranging needs, from cell culture to imaging-based studies of biological tissues and bioassays.  For more information, please visit https://www.microscope.healthcare.nikon.com/bioimaging-centers/nikon-bioimaging-labs/boston-usa or contact us at 1-800-52-NIKON.

 

For further information on Lunaphore:

Lindsey Rodger, Head of Communications

[email protected]

 

Bio-Techne Corporation (NASDAQ: TECH)

David Clair, Vice President, Investor Relations & Corporate Development

[email protected]

612-656-4416

 

For further information on Nikon Instruments Inc:

Stephen Ross, Director, Product and Marketing, Nikon Instruments Inc

[email protected]

 

Nikon BioImaging Lab:

Michael Yang, Scientific Group Leader, Nikon BioImaging Lab

Gaurav Joshi, Senior Scientist, Nikon BioImaging Lab

[email protected]

 

MINNEAPOLIS, MN and LAUSANNE, Switzerland – March 21, 2023 – Bio-Techne Corporation (NASDAQ: TECH) today announced that its spatial biology brand, Lunaphore, will host an in-person symposium at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego from April 5-10, to discuss the recent paradigm shift in cancer research, driven by innovative spatial technologies. Lunaphore will present the transformative impact of the recently launched, fully automated, same-section spatial multiomics application accelerating translational research.

An international group of leading experts will explore how the breakthrough research enabled by Lunaphore’s end-to-end COMET™ product portfolio is paving the way for novel personalized immuno-oncology therapies. The symposium aims to promote interactions between researchers and prominent innovators from industry and academia and presents a unique opportunity for fostering collaborations.

Lunaphore will also reveal upcoming feature releases, further enhancing COMET capabilities for specific research needs and broadening its applications. These enhancements will ensure the quantitative detection of essential biomarkers with minimal antibody concentrations for customized hyperplex assays, ultimately redefining cancer research.

Dinner Symposium details:

Spatial biology: reinvent cancer research with multiomics and innovative workflows

Location: Hard Rock Café Hotel San Diego (Adjacent to conf. center)

Date & Time: April 8, 2024 | 6:30 PM PST

Confirmed guest speakers:

Jared Burks, Ph.D. Professor, Co-Director of the Flow Cytometry & Cellular Imaging Core Facility, University of Texas, MD Anderson Cancer Center (USA)

Sammy Ferri-Borgogno, Ph.D., Instructor, The University of Texas MD Anderson Cancer Center

Free registration: https://lunaphore.com/our-events/aacr-annual-meeting-2024/

In addition, during the conference, Dr. Karuna Ganesh MD, Ph.D., Assistant Member and Medical Oncologist, Memorial Sloan Kettering Cancer Center, will highlight her work on the role of plasticity during tumorigenesis facilitated by the COMET™ platform during the Bayard Clarkson Symposium, taking place on Monday, April 8 from 10:15 to 11:45.

Two poster presentations will also showcase novel datasets highlighting the industry-leading capabilities of Lunaphore’s solutions to advance cancer research.

Poster presentation details:

Unveiling the spatial dynamics of the tumor microenvironment: integrated RNA and protein profiling on the same slide through automated spatial multiomics analysis

Poster number: 3797

Date & Time: Monday, April 8 | 1:30 PM – 5:00 PM

Presenter: Arec Manoukian, Ph.D. Application Development Scientist, Lunaphore

 

HOST-Factor: A comprehensive platform for single-cell highplex immunofluorescence staining, digital imaging, spatial mapping, and quantitative analysis of the tumor microenvironment

Poster number: 28. Section: 10

Date & Time: Tuesday, April 9 | 1:30 PM – 5:00 PM

Presenter: Janusz Franco-Barraza, Ph.D., Research Assistant Professor, Manager of  Spatial Immuno-Proteomics Facility, Fox Chase Cancer Center (USA).

 

During the conference, Lunaphore’s scientists will be available at booth #415 to provide live demonstrations of the COMET system and access to raw data on various cancer types.

To book a meeting, learn more about Lunaphore’s presence at the conference, and view the full list of posters or presentations showcasing our technologies, please visit Lunaphore’s website.

 

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

About Lunaphore

Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.

About COMET™

COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET™ enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/

 

For further information on Lunaphore:

Lindsey Rodger, Head of Communications
[email protected]

 

Bio-Techne Corporation (NASDAQ: TECH)

David Clair, Vice President, Investor Relations & Corporate Development
[email protected]
612-656-4416